跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 96,177 条关于
“CCNE1-amplified ovarian cancer”
全部
96,177
临床试验
77,956
药物
2,307
机构
1,107
资讯
14,807
9个月前
Avenzo's CDK2 Inhibitor AVZO-021 Shows Promising Activity in Breast and Ovarian Cancer Patients
5个月前
Incyclix Bio Secures $5M Series B Extension to Advance CDK2 Inhibitor INX-315 in Resistant Breast and Ovarian Cancers
去年
FDA Grants Fast Track Designation to Incyclix Bio's INX-315 for CCNE1-Amplified Platinum-Resistant Ovarian Cancer
去年
Incyclix Bio's INX-315 Shows Promise in Advanced Breast and Ovarian Cancers
去年
Molecular Testing Advances Personalized Treatment Strategies in Ovarian Cancer
去年
Incyclix Bio Raises $11.25 Million to Advance CDK2 Inhibitor INX-315 for Treatment-Resistant Breast and Ovarian Cancers
5个月前
Gilead Exercises Option for Kymera's KT-200 CDK2 Degrader, Triggering $45M Milestone Payment
去年
Repare Therapeutics Advances Oncology Pipeline with Promising Clinical Data
去年
Repare Therapeutics to Present Phase 1 MYTHIC Trial Data of Lunresertib and Camonsertib Combination in Advanced Cancers
去年
Dual SHP2 and FGFR2 Inhibition Shows Promise in Treatment-Resistant Gastric Cancer
第 1 页，共 1481 页
上一页
下一页
